Alembic Pharmaceuticals

1,003.20
+0.90
(0.09%)
ann
There are new updates from the company19 hours ago
Viewcross
right
Market Cap
19,719.21 Cr
EPS
29.68
PE Ratio
34.59
Dividend Yield
1.10 %
Industry
Healthcare
52 Week High
1,303.90
52 Week Low
725.20
PB Ratio
3.79
Debt to Equity
0.18
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from11 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+45.45 %
+45.45 %
Hold
Hold+45.45 %
+45.45 %
Sell
Sell+9.09 %
+9.09 %

Company News

View All News
Caret
positive
Alembic Pharmaceuticals: $12 Million Acquisition Expands US Footprint5 days ago
Alembic Pharmaceuticals' subsidiary has acquired Utility Therapeutics Ltd. for $12 million, expanding its UTI drug portfolio in the US. The deal includes 100% ownership and is expected to close within 30 days. Alembic aims to commercialize Utility's FDA-approved and pipeline products in the US market.
positive
Alembic Pharmaceuticals' unit has purchased Utility Therapeutics for $12 million. This acquisition aims to expand Alembic's range of urinary tract infection (UTI) drugs in the United States market.
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,669.40
#1 4,00,544.98
35.18
#1 54,729.00
12.06
#1 10,980
-18.99
48.33
6,988.50
1,85,522.72
83.40
9,360.00
0.89
2,117
23.05
68.54
1,491.70
1,20,485.78
23.71
28,409.50
7.12
5,291
30.28
54.26
3,326.10
1,12,570.34
59.20
11,539.40
11.59
1,911
10.91
62.08
1,289.80
1,07,642.98
#1 19.71
33,741.20
12.36
5,725
21.14
54.13
2,432.20
1,00,383.89
50.14
12,207.40
19.57
1,925
-10.91
59.65
985.80
99,194.55
21.52
22,573.80
13.82
3,977
-0.19
69.99
1,938.50
88,530.42
27.52
22,192.10
#1 19.94
3,024
#1 112.49
53.08
34,730.00
73,798.83
51.77
6,409.15
10.80
1,417
27.83
64.97
1,153.20
66,978.04
19.91
31,378.10
17.55
3,366
-0.50
63.70

Automatic Screeners on ScanX

Forecast
Actual
Growth Rate
Revenue Growth
7.32 %
Net Income Growth
-5.49 %
Cash Flow Change
-89.05 %
ROE
-12.21 %
ROCE
6.31 %
EBITDA Margin (Avg.)
1.82 %

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
1,641
2,429
2,689
3,941
4,778
5,989
6,709
7,122
6,183
6,446
7,773
Fixed Assets
547
708
799
993
1,159
1,552
1,788
1,798
2,398
2,547
2,524
Current Assets
891
1,511
1,373
1,825
1,958
2,463
2,652
2,861
2,910
3,079
4,088
Capital Work in Progress
83
93
396
1,010
1,551
1,846
2,183
2,304
601
524
837
Investments
0
53
50
42
49
18
236
118
96
93
127
Other Assets
1,011
1,575
1,444
1,896
2,019
2,573
2,502
2,902
3,087
3,282
4,285
Total Liabilities
1,641
2,429
2,689
3,941
4,778
5,989
6,709
7,122
6,183
6,446
7,773
Current Liabilities
684
747
693
1,144
1,490
1,752
1,281
1,717
1,637
1,455
2,412
Non Current Liabilities
72
84
94
576
570
1,047
361
168
175
172
171
Total Equity
885
1,597
1,902
2,220
2,718
3,190
5,067
5,238
4,371
4,818
5,190
Reserve & Surplus
847
1,560
1,865
2,182
2,681
3,182
5,028
5,198
4,331
4,779
5,152
Share Capital
38
38
38
38
38
38
39
39
39
39
39

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
3
417
-286
-69
115
-127
26
-37
14
45
-37
Investing Activities
-256
-307
-486
-884
-756
-731
-840
-372
-448
-321
-568
Operating Activities
172
948
329
312
812
449
1,463
552
724
803
88
Financing Activities
87
-224
-129
503
59
155
-597
-217
-262
-438
444

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
69.48 %
69.48 %
69.48 %
69.48 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.67 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
4.52 %
4.46 %
4.32 %
3.94 %
4.17 %
3.94 %
DIIs
10.92 %
11.17 %
11.36 %
11.56 %
11.69 %
12.06 %
12.43 %
12.76 %
13.31 %
13.40 %
13.93 %
14.50 %
15.38 %
15.47 %
16.05 %
16.06 %
16.43 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
10.99 %
10.78 %
11.43 %
9.57 %
9.22 %
8.91 %
9.12 %
9.21 %
9.08 %
8.98 %
8.24 %
8.00 %
7.41 %
7.48 %
7.36 %
7.26 %
7.07 %
Others
8.61 %
8.57 %
7.73 %
9.39 %
9.47 %
9.41 %
8.84 %
8.42 %
8.00 %
8.01 %
8.22 %
3.37 %
3.14 %
3.13 %
3.04 %
2.90 %
2.88 %
No of Share Holders
0
0
99,809
1,01,686
1,23,059
1,10,038
1,06,437
1,01,457
1,03,811
97,607
89,552
85,212
76,567
74,829
91,429
93,944
91,336

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 4 4 5.5 10 14 10 8 11 11
Dividend Yield (%) 0.00 0.73 0.74 1.03 1.04 1.89 2.13 0.81 1.18 1.1

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
05 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
05 Aug 2025 995.90 1,001.60
29 Jul 2025 DIVIDEND Dividend
₹ 11.00 /share
29 Jul 2025 887.60 1,001.60
06 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
06 May 2025 849.90 887.60
03 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
03 Feb 2025 1,019.60 907.30
07 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
07 Nov 2024 1,160.20 1,079.90
22 Jul 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
22 Jul 2024 869.15 1,119.10
15 Jul 2024 DIVIDEND Dividend
₹ 11.00 /share
15 Jul 2024 1,001.35 981.85
28 Jul 2023 DIVIDEND Dividend
₹ 8.00 /share
28 Jul 2023 554.40 777.20
18 Aug 2022 DIVIDEND Dividend
₹ 10.00 /share
17 Aug 2022 786.60 654.70
21 Jul 2021 DIVIDEND Dividend
₹ 14.00 /share
19 Jul 2021 1,006.80 939.65

Announcements

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 201814 hours ago
Announcement under Regulation 30 (LODR)-Change in Management19 hours ago
Announcement under Regulation 30 (LODR)-Change in Management19 hours ago
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 20153 days ago
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 20154 days ago
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 20155 days ago
Announcement under Regulation 30 (LODR)-Newspaper Publication5 days ago
Volume Movement6 days ago
Clarification sought from Alembic Pharmaceuticals Ltd6 days ago
Alembic Pharmaceuticals Receives USFDA Final Approval For Doxorubicin Hydrochloride Liposome Injection9 days ago
Closure of Trading WindowJun 26, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJun 25, 2025
Alembic Pharmaceuticals Limited Has Received Establishment Inspection Report (EIR) For Its API-III Facility At KarakhadiJun 18, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 18, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Jun 17, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 17, 2025
Business Responsibility and Sustainability Reporting (BRSR)Jun 16, 2025
Submission Of Notice Of The 15Th Annual General Meeting Of The CompanyJun 16, 2025
Submission Of Notice Of The 15Th Annual General Meeting Of The CompanyJun 16, 2025
Reg. 34 (1) Annual Report.Jun 16, 2025
Announcement under Regulation 30 (LODR)-Credit RatingJun 12, 2025
Announcement under Regulation 30 (LODR)-Credit RatingJun 12, 2025
Intimation Of Record Date For Payment Of Dividend On Equity Shares For The Financial Year Ended 31St March 2025Jun 11, 2025
USFDA Inspection At Alembic Pharmaceuticals LimitedS API - I & II Facility Located At Panelav.May 31, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 30, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 23, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 23, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 21, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 20, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 16, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 15, 2025
Please Find Attached Herewith Copy Of Newspaper AdvertisementMay 15, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMay 15, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 15, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 13, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 12, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 07, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 07, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 06, 2025
Announcement Under Regulation 30 Of SEBI LODRMay 06, 2025
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/sMay 06, 2025
Financial Results For The Quarter And Financial Year Ended 31St March 2025May 06, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 06, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 06, 2025
Board Meeting Outcome for Please Find Attached Herewith The Outcome Of Board MeetingMay 06, 2025
Board Meeting Outcome for Please Find Attached Herewith The Outcome Of Board MeetingMay 06, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 ("Listing Regulations 2015")May 05, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 02, 2025
Announcement Under Regulation 30 Of SEBI Regulations 2015Apr 29, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Apr 26, 2025

Technical Indicators

RSI(14)
Neutral
56.02
ATR(14)
Less Volatile
34.26
STOCH(9,6)
Neutral
44.34
STOCH RSI(14)
Neutral
57.24
MACD(12,26)
Bullish
2.34
ADX(14)
Strong Trend
36.54
UO(9)
Bearish
42.30
ROC(12)
Uptrend And Accelerating
7.42
WillR(14)
Neutral
-57.14

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Kotak Small Cap Fund Direct-Growth
0.00%
-3427766
-2.01%
-1.89%
DSP Midcap Direct Plan-Growth
0.00%
-2961070
-1.61%
-1.47%
DSP Small Cap Direct Plan-Growth
0.00%
-1500000
-0.94%
-0.92%
Axis Small Cap Fund Direct-Growth
0.00%
-1445780
-0.59%
-0.54%
DSP Healthcare Fund Direct - Growth
0.00%
-1428180
-4.91%
-4.29%
DSP ELSS Tax Saver Fund Direct Plan-Growth
0.00%
-1420394
-0.85%
-0.75%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth
0.00%
-1074403
-1.99%
-1.77%
DSP Aggressive Hybrid Fund Direct-Growth
0.00%
-810789
-0.74%
-0.66%
DSP Top 100 Equity Direct Plan-Growth
0.00%
-608603
-1.03%
-0.95%
Edelweiss Mid Cap Direct Plan-Growth
0.00%
-520911
-0.53%
-0.49%
ICICI Prudential Smallcap Fund Direct Plan-Growth
0.00%
-409890
-0.51%
-0.45%
Mirae Asset Healthcare Fund Direct - Growth
0.00%
-289401
-1.10%
-0.94%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct-Growth
0.00%
-240291
-3.00%
-2.57%
Edelweiss Multi Cap Fund Direct - Growth
0.00%
-232711
-0.85%
-0.77%
Edelweiss Flexi Cap Fund Direct-Growth
0.00%
-195896
-0.75%
-0.67%
DSP Multicap Fund Direct - Growth
0.00%
-127660
-0.57%
-0.46%
HDFC Retirement Savings Fund - Hybrid Equity Plan Direct-Growth
0.00%
-125000
-0.77%
-0.68%
DSP Multi Asset Allocation Fund Direct - Growth
0.00%
-112492
-0.36%
-0.33%
DSP Equity Savings Fund Direct-Growth
0.00%
-102300
-0.35%
-0.33%
HDFC Multi Cap Fund Direct - Growth
0.00%
-92985
-0.05%
-0.05%
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth
0.00%
-66608
-0.30%
-0.28%
DSP Value Fund Direct - Growth
0.00%
-63294
-0.64%
-0.58%
Bajaj Finserv Multi Cap Fund Direct-Growth
0.00%
-58660
-0.86%
-0.13%
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth
0.00%
-42182
-1.29%
-1.15%
SBI Nifty Smallcap 250 Index Fund Direct - Growth
0.00%
-41784
-0.30%
-0.28%

About Alembic Pharmaceuticals

Alembic Pharmaceuticals is an India-based company that manufactures and markets generic pharmaceutical products globally. It operates in India Formulations, International Generics, and Active Pharmaceutical Ingredients (API) segments. The company has state-of-the-art research and manufacturing facilities approved by regulatory authorities, including the US FDA. Alembic produces a range of generics across chronic segments, including Dermatology, Anti-Infective, Cardiology, and Anti-Diabetic therapies. The company has manufacturing facilities in Gujarat and Sikkim, with research and development centers in Vadodara, Hyderabad, and New Jersey. Alembic has expanded its operations through acquisitions, joint ventures, and international subsidiaries, focusing on developing and marketing generic drugs in various global markets.
Chairperson NameChirayu R Amin